DVX201

BIOLOGICAL2 trials

Sponsors

Coeptis Therapeutics

Conditions

AML, Adult RecurrentCOVID-19 PneumoniaMDS

Phase 1

Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS

CompletedNCT04901416

Coeptis TherapeuticsAML, Adult Recurrent, MDS

Start: 2021-12-15End: 2024-06-04Updated: 2024-07-19

Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19

CompletedNCT04900454

Coeptis TherapeuticsCOVID-19 Pneumonia

Start: 2021-08-01End: 2022-07-01Updated: 2024-04-08

Related Papers

The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19.

2024-12-271 citations